ESMO 2023

My highlights of ESMO23 in metastatic breast cancer

Highlights in eBC

Preoperative checkpointinihition in ER+ disease

5 year follow-up

Remarkable efficacies in patients with HER2+ mBC with…

New 3rd line therapy for RCC

Clearing up non-clear cell RCC

Early use of enzalutamide in advanced prostate cancer

The FGFR story in bladder cancer at ESMO23

Lu-PSMA leads forward

Tarlatamab in SCLC

Datopotamab deruxtecan - new SOC in 2nd line adv/met…

Perioperativ immunotherapy for all resectable stage…

ALINA - immediate change of practice!

My highlights from ESMO 2023

New and better biomarkers are needed!

Anticipated updates and exciting new data for…

What was the most exciting news at ESMO23?

What is your definition of triple-negative breast…

Negative EFS results from NeoTrip

ER-low corresponds diagnostically to ER-0 breast cancer

My highlights of ESMO23 in early breast cancer

Pembrolizumab solidifies as SOC in early-stage TNBC

Neoadjuvant IO - is their new strategy in HR+ breast…

Consolidation of data in early HR+ and triple-negative…

Prognostic score in early HR+/HER2-BC: translational…

MonarchE - trial update

HR+ study with > 20 % PCR

Use of immunotherapy in the perioperative setting of…

Analysis of tumour microenvironment and…

Metabolomics reveal differential expression of OMEGA 3…

Immunoncology in eBC - triple negative and more?

Ribociclib effective in all subtypes

Detailed view of nodal-negative patients

Preoperative checkpointinihition in ER+ disease

Highlights in eBC

Carry-over effects in monarchE confirmed

Clinically relevant effect of pembro also in PCR

Our guidelines are correct

5 year follow-up

Punti salienti in eBC

Nouvelles données sur l'immunothérapie néoadjuvante

MonarchE - mise à jour de l'essai

La Metabolomica svela l’importanza di OMEGA 3 & OMEGA 6…

How to organize a molecular tumorboards in breast…

What was the most exciting news at ESMO23?

ADCs in HER2+, HER2low and TNBC - what is the future of…

New ADC for metastatic breast cancer?

Improvement of therapy outcome by app-based patient…

OP seems to be dispensable for super responders

Even more new generation ADCs in breast cancer?

My highlights of ESMO23 in metastatic breast cancer

ADC + Immunotherapy - the BEGONIA study paradigm

T-DXd - new standard of care for brain mets?

Duvalumab + Dato-DXd effective

T-DXd in HER2+ patients with brain metastases

TROP2 expression as a potential mechanism of resistance…

Highlights in mBC

T-DXd also effective for brain metastases

Can surgery be spared following primary systemic…

HER2DX in the PHERgain trial

Remarkable efficacies in patients with HER2+ mBC with…

Still on track for success in HER2-low MBC

Improved oncological therapy with the smartphone

HS20089 - a novel ADC is coming for TNBC

New ADC in HR+ disease

Dato-DXd - new player in advanced luminal disease

OP-1250 (Palezestrant) confirms the role of SIRDs after…

DATO-DX - where is it going?

Benefit for SG even after intensive pretreatment

Robust data from the monarchE

Fulvestran better than anastrozole, but no survival…

TULIP: Trastuzumab duocarmazine without OS benefit

Patient-centered molecular medicine - a new approach

Our guidelines are correct

Lo studio BEGONIA nelle paziento con tumore triplo…

OP-1250 (Palezestrant) ulteriore conferma del ruolo dei…

Czy możliwa jest rezygnacja z chirurgii po indukcyjnym…

Punti salienti in mBC

La expresión de TROP2 como potencial mecanismo de…

T-DXd - nowy standard postępowania w przerzutach do…

ADC + Immunothérapie: L'exemple de l'étude BEGONIA par…

Dato-DXd - nowy gracz w zaawansowanym raku luminalnym

HER2DX en el estudio PHERgain

Targeted therapy will move forward - but more robust…

The optimal timing of RT after radical prostatectomy…

What is the future of immune therapy in prostate…

Precision medicine at mCRCP

EMBARK - Quality of Life

TITAN: ultra-low PSA = best prognosis

STAMPEDE. Bone prediction not for everyone - better…

Brave New World in mCRPC

Salvage radiotherapy the new standard

When immunotherapy is probably not the best choice: The…

RADICALS RT: Trial and controversies

Negative data for pembrolizumab in mHSCPC & mCRPC

Combination of radioligand therapy with chemotherapy…

Embark without fear

IO therapy in metastatic prostate cancer.

CXCR2 inhibitor in PCa

Immunotherapy in metastatic PCa

PSMA FORE: Trial and controversies

Osteoprotection at mHSPC

Lu-PSMA leads forward

EMBARK expands ENZA indication to PCa

Big data and AI prediction tools

Early use of enzalutamide in advanced prostate cancer

PSMAfore unleashes urooncologic opportunity

ENZA P:Trial and controversies

CXCR2 hämmare och prostatacancer

Cuando la inmunoterapia probablemente no es la mejor…

Big Data och AI för prediktion vid prostatacancer

STAMPEDE data. Skelettstärkande och riskstratifiering.

Immunterapi vid prostatacancer

FGFR inhibitors and ADC combinations in urothelial…

Part1: New standard of care in first line urothelial…

Chemo-IO establishes itself in the first-line treatment…

DAD, DAD-IO

The FGFR story in bladder cancer at ESMO23

Amazing new data in bladder cancer

New SoC in firstline bladder cancer

EV + Pembro as standard of care in first-line therapy…

When the history of ADC is written: Redefining…

FGFR inhibitors: What is the best scenario for this…

Inhibidores de FGFR: Cual es el mejor escenario para…

Στιγμιότυπα για τον καρκίνο των νεφρών και της…

L'histoire du FGFR dans le cancer de la vessie à…

Is de-escalating therapy ready for prime-time?

Important new treatment option but only for subset of…

Intermittent therapy also possible with TKIs

Kidney cancer highlights at ESMO23

Clearing up non-clear cell RCC

Belzutifan in later lines of therapy

New mode of action in mRCC - ready for prime time?

Belzutifan - whats next kidney cancer?

Moving patients to the neoadjuvant setting in…

Scene is set for inductive immunotherapy

ALINA - a new paradigm in operated NSCLC with…

Neoadjuvant chemo-immunotherapy new standards in early…

Adjuvant alectinib in patients with early-stage ALK+…

Big improvements in early stage and a subset of…

Perioperativ immunotherapy for all resectable stage…

Perioperative IO: OS-benefi from KEYNOTE-671

ALINA - immediate change of practice!

Circulating DNA in AEGEAN trial

Substantial improvement in local regional NSCLC

Gros progrès dans les traitments medicaeux des stades…

ALINA - un nouveau paradigme dans cBNPC avec la fusion…

Perioperatieve chemo-immunotherapie voor alle patienten…

Les points forts de l'ESMO 2023

Activating EGFR-mutation - what's coming up?

Rare oncogenic alterations: landmark results on exon 20…

Evolving landscape of ADCs

Substantial improvement in rare alterations

Brain metastases – options to improve the systemic…

Amivantamab as a new SoC for EGFR Exon 20…

MARIPOSA: Trial and controversies

New standard of care for metastatic EGFR exon 20…

Datopotamab deruxtecan - new SOC in 2nd line adv/met…

TROPION-Lung01: positive development

Treatment sequences for EGFR-mutated Patients

Big improvements in early stage and a subset of…

PAPILLON - bringing together therapy for the 1st line

Amivantamab at progression? MARIPOSA-2 trial

My highlights from ESMO 2023

Amivantamab upfront? MARIPOSA trial

Adagrasib + pembrolizumab in patients with KRASG12C…

Changing treatment landscape in EGFR-mutated NSCLC

NRG fusions: a new drugable target?

Do ADCs have brain activity?

RET-TKI: Standard in 1st line RET fusion-positive NSCLC

Practice changing results on exon 20 insertion mNSCLC

MARIPOSA II: Trial and controversies

By unanimous decision and still the champion –…

Does immunotherapy still have a place in EGFR-positive…

Quelles séquences thérapeutiques pour les patients EGFR…

I miei punti salienti di ESMO 2023

Les points forts de l'ESMO 2023

Nieuwe standaard voor gemetastaseerd EGFR exon20…

Amivantamab at progression? MARIPOSA-2 trial

Veränderte Behandlungslandschaft bei EGFR-mutiertem…

Amivantamab upfront? MARIPOSA trial

Heeft immunotherapie nog een plek in de behandeling van…

Datopotamab deruxtecan - new SOC in 2nd line adv/met…

L’amivantamab, nouveau standard de traitement pour les…

Tarlatamab in SCLC

New hope for patients with SCLC

New data on sarkomas

New data on H&N Cancer

Precision oncology in CUP

Update on gynaecological cancers

Evolution of the revolution - the RUBY trial

First data on luveltamab in multiline treatment for…